Статья
Гипертриглицеридемия: этиология, патогенез, диагностика
Обзор посвящен современным представлениям об этиологии и патогенезе гипертриглицеридемии (ГТГ), а так же ее причинной роли в развитии ряда заболеваний. Приведены данные об обмене триглицеридов в норме, основных причинах ГТГ, ее клиническом значении и диагностических подходах у пациентов с этим нарушением. ГТГ, несмотря на важную роль в развитии атеросклероза, панкреатита, болезни Альцгеймера, преэклампсии, остается мало освещенной проблемой для практикующего врача.
1. Ginsberg HN. New perspectives on atherogenesis. Role of abnormal triglycerid-rich lipoprotein metabolism. Circulation 2002; 106: 2137-42.
2. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. Circulation 1999; 99: 2901-7.
3. Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to treatment. Am J Cardiol 2001; 87: 1174-80.
4. Manninen V, Tenkanen L, Koskinen P, et al. Helsinki Heart Study. Circulation 1992; 85: 37-45.
5. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36.
6. Hokanson JE, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of highdensity lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc risk 1996; 3: 213-9.
7. Sprecher DL, Harris BV. Higher triglycerides, lower high-density lipoprotein cholesterol and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. Circulation 1996; 94: 3239-45.
8. Okura Y, Hayashi K. Diagnostic evaluation of acute pancreatitis in two patients with hypertriglyceridemia. World J Gastroenterol 2004; 10(24): 3691-5.
9. Stojakovic T, Scharnagl H, Marz W. Apo E: crossroads between Alzheimers disease and atherosclerosis. Sem vasc med 2004; 4(3): 279-85.
10. Evans V, Kastelein JJP. Lipoprotein lipase deficiency-rare or common? Cardiovascular drugs and therapy 2002; 16: 283-7.
11. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regylation. J Lipid Res 2002; 43: 1997-2006.
12. Durrington P. Dyslipidaemia. Lancet 2003; 362: 717-31.
13. Lusis ALJ, Fogelman AlM. Genetic Basis of Atherosclerosis. Clinical Implications. Circulation 2004; 110: 2066-71.
14. Le N-A, Cibson JC. Independent regulation of plasma apolipoproteins CII and CIII concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these Lipoproteins. J Lipid Res 1988; 29: 669-77.
15. Sadao Takahashi, Juro Sakai. The Very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoproten receptor Proctor SD. Retention of fluorescent labeled chylomicron remnants within the intima of the arterial wall evidence that. Eur J Clin Invest 1998; 28: 497-8.
16. Ansell BJ, Watson KE. High-density lipoprotein function. JACC 2005; 46: 1792-8.
17. Ashen MD, Blumenthal RS. Low HDL Cholesterol levels. N Engl J Med 2005; 353: 1252-60.
18. Bahaev VR. Macrophage LPL promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient wice. J Biol Chem 2000; 275: 26293-9.
19. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, final report. Circulation 2002; 106(25): 3157-373.
20. Hata Y, Nakajima K. Life-style and serum lipids and lipoproteins. J Atheroscler Thromb 2000; 7(4): 177-97.
21. Lee WY, Jung CH, Park JS, et al. Effects of smoking, alcohol, exercise, education, and family history on the metabolic syndrome as defined by the ATP III. Diabetes Res Clin Pract 2005; 67(1): 70-7.
22. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83: 25F-9.
23. Erkelens DW. Diabetic dyslipidaemia. Eur Heart J 1998; 19(Suppl): H27-30.
24. Horward BV. Insulin resistance and lipid metabolism. Am J Cardiol 1999; 84; 28j-32.
25. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003; 5(Suppl 1): S19-27.
26. De Graaf J, van der Vleuten G, Stalenhoef AF. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Sem vasc med 2004; 4(3): 229-39.
27. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial hyperlipidemia and risk of coronary heart disease. Hum molec genet 2004; 13: R149-60.
28. Tompson GP. A handbook of hyperlipidaemia. Current Science, ltd. London 1990: 118-24.
29. Talmud PJ. Genetic determinants of plasma triglycerides: impact of rare and common mutations. Curr Atheroscler Rep 2001; 3: 191-9.
30. Smelt AHM, de Beer F. Apolipoprotein E and Familial Dysbetalipoproteinemia: clinical, biochemical and genetic aspects. Sem vasc med 2004; 4(3): 249-57.
31. Wittrup HH, Nordestgaard BJ. A common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in women but not in men. Circulation 2000; 101: 2393-7.
32. Jukema JW. The Asp 9 Asn mutation in the Lpl gene is associated with increased progression of coronary atherosclerosis. Circulation 1996; 94: 1913-8.
33. Talmud PJ, Dujac S. Substitution of D9N of LPL markedly augment risk of coronary heart disease in man smokes. Atherosclerosis 2000; 149: 75-81.
34. Murase T, Ymada N. Decline of postheparin plasma lipoprotein lipase in acromegalic patients. Metabolism 1980; 29: 666-72.